Nephrology Drugs Market Size, Share, Analysis, Trends, Growth, 2032

Nephrology Drugs Industry Prospective:

The global nephrology drugs market size was evaluated at $16.35 billion in 2023 and is slated to hit $28.96 billion by end of 2032 with a CAGR of nearly 6.56% between 2024 and 2032.  

Request Free Sample

Nephrology Drugs Market: Overview

Nephrology drugs are prescribed by doctors for treating various kinds of kidney ailments such as kidney infections, chronic kidney disorders, diabetic nephropathy, and acute kidney injuries. Moreover, surging occurrence of the kidney diseases among the aging population has enhanced the demand for nephrology drugs.

Key Insights

• As per the analysis shared by our research analyst, the global nephrology drugs market is projected to expand annually at the annual growth rate of around 6.56% over the forecast timespan (2024-2032)
• In terms of revenue, the global nephrology drugs market size was evaluated at nearly $16.35 billion in 2023 and is expected to reach $28.96 billion by 2032.
• The global nephrology drugs market is anticipated to grow rapidly over forecast timeline owing to an increase in the incidences of kidney failures and adoption of unhealthy lifestyle.
• In terms of product type, the ACE inhibitors segment is slated to register the highest CAGR over the forecast period.
• Based on route of administration, the oral segment is predicted to lead the segmental space in the upcoming years.
• Region-wise, the Asia-Pacific nephrology drugs industry is projected to register the fastest CAGR during the projected timespan.

Request Free Sample

Nephrology Drugs Market: Growth Factors

Rise in the frequency of kidney disorders can prop up the scope of the global market expansion over 2024-2032

An increase in the incidences of kidney failures and adoption of unhealthy lifestyle is expected to drive the global nephrology drugs market demand. Furthermore, a surge in the intake of alcoholic drinks and rise in the obesity in individuals due to sedentary lifestyle can favor the growth of the market across the globe. An increment in demand for diagnostic tests can propel the global market expansion in the coming years.

An increase in the product approval and launching of new products can spike the global market expansion in the forecasting years. For instance, in September 2023, the U.S. FDA approved Jardiance® for treating adult persons having chronic kidney ailment. In January 2024, Sun Pharma and Bayer AG joined hands for launching a medicine for treating chronic kidney disorder.

Nephrology Drugs Market: Restraints

Rising product costs can impede the expansion of the global industry by 2032

Growing product costs due to increase in the import costs of raw materials along with disruptions in the supply chain activities can deter the growth of the global nephrology drugs industry.

Nephrology Drugs Market: Opportunities

Innovations witnessed in the pharmaceutical sector to open new growth avenues for the global market

Technological breakthroughs in the field of pharmaceutical sector will open a slew of growth opportunities for the global nephrology drugs market.

Nephrology Drugs Market: Challenges

Less awareness about treating kidney disorders in developing & underdeveloped countries to challenge the global industry surge

Lack of awareness of kidney ailments among the people in emerging economies as well as under-developed countries can challenge the global nephrology drugs industry surge in next eight years.

Nephrology Drugs Market: Segmentation

The global nephrology drugs market is divided into product type, route of administration, distribution channel, and region.                                         

In product type terms, the nephrology drugs market across the globe is segregated into beta blockers, ACE inhibitors, calcium channel blockers, and diuretics segments. Furthermore, the ACE inhibitors segment, which acquired nearly 56% of the global market revenue in 2023, is predicted to register the fastest rate of growth in the forecast period. The expansion of the segment in the coming eight years can be due to use of the ACE inhibitors in reducing high blood pressure in individuals. These medicines are used for treating renal disorders caused due to hyper-tension. Furthermore, they are effective in the healthcare sector as these medicines offer long-term relief for patients & can effectively manage kidney disorders caused due to diabetes. An increase in heart ailments will also prop up the segmental surge.

On the basis of route of administration, the global nephrology drugs industry is segmented into parenteral and oral segments. Additionally, the oral segment, which accumulated a foremost share of the global industry in 2023, is expected to dominate the segmental space in the coming years. The segmental surge from 2024 to 2032 can be owing to ease of administrating the oral drugs along with its frequent use & safety. Apart from this, oral nephrology drugs are cost-effective and are hence preferred by a large geriatric population base.

Based on the distribution channel, the global nephrology drugs market is divided into online and offline segments.

Nephrology Drugs Market: Report Scope

Nephrology Drugs Market: Regional Insights

North America is predicted to maintain the leading position in the global nephrology drugs market in the upcoming years

North America, which accounted for nearly two-fifths of the global nephrology drugs market proceeds in 2023, is expected dominate the global market in the next decade. In addition to this, the regional market expansion in the next couple of years can be due to surging cases of kidney ailments in the countries such as Canada and the U.S. A rise in the diabetic population in these countries will further contribute to the growth of the industry in the sub-continent. Favorable compensation policies and availability of advanced technologies to manufacture nephrology drugs will further propel the expansion of the market in North America.

The Asia-Pacific nephrology drugs industry is slated to register the fastest CAGR in the forecast timeframe. The elevation of the industry in the APAC can be credited to rise in the presence of aging populace prone to chronic kidney ailments in China, India, and Japan. Rise in the healthcare budget and increasing in the drug production capacities in India and China will proliferate the profitability of the industry in the region.

Nephrology Drugs Market: Competitive Space

The global nephrology drugs market profiles key players such as:

• Johnson & Johnson Inc.
• Teva Pharmaceuticals Industries Limited
• GlaxoSmithKline PLC
• Amgen Inc.
• F-Hoffmann La Roche
• Akebia Therapeutics Inc.
• AstraZeneca
• FibroGen Inc.
• AbbVie Inc.
• Pfizer Inc.

The global nephrology drugs market is segmented as follows:

By Product Type

• Beta Blockers
• ACE Inhibitors
• Calcium Channel Blockers
• Diuretics

By Route of Administration

• Parenteral
• Oral

 By Distribution Channel

• Offline
• Online

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa